NY-IFF
IFF (NYSE:IFF) today announced that it will webcast its 2022 Investor Day presentation on Wednesday, Dec. 7, 2022, beginning at 1:00 p.m. ET.
Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 202629.10.2025 08:00:00 CET | Press release
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023 Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe.
Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 08:00:00 CET | Press release
Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performanc
Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care29.10.2025 07:28:00 CET | Press release
Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/ Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care. Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance. These developments come amid China’s ongoing demographic transformation. By
Aramco and Yokogawa Achieve a Major Milestone with Commissioning of Multiple Autonomous Control AI Agents at Major Gas Facility29.10.2025 03:00:00 CET | Press release
- Groundbreaking deployment successfully optimizes gas treatment unit, reducing energy and chemical use - Yokogawa Electric Corporation (TOKYO: 6841, “Yokogawa”), a leader in process automation technology, announces it has achieved a historic milestone in the deployment of industrial artificial intelligence (AI) solutions with Aramco, one of the world’s leading integrated energy and chemicals companies. Multiple autonomous control AI*1 agents have been successfully implemented by Yokogawa at Aramco’s Fadhili Gas Plant in the Kingdom of Saudi Arabia to enhance operational efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028792329/en/ Fadhili Gas Plant (Courtesy of Aramco) The AI solution developed by Yokogawa uses multiple, coordinated AI agents of the Factorial Kernel Dynamic Policy Programming (FKDPP)*2 reinforcement learning-based AI algorithm to directly and autonomously control and optimize acid gas removal
FPT Signs Platinum Partnership with Clearlake Capital to Accelerate Digital Transformation in Private Equity Sector29.10.2025 02:10:00 CET | Press release
FPT, a global leader in digital transformation, announced the signing of a Platinum Partnership Agreement with Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies. This strategic alliance marks a bold step in FPT’s expansion into the private sector, to deliver transformative technology solutions across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028209395/en/ “This Platinum Partnership with Clearlake is a proud milestone in our journey to become a global digital transformation powerhouse - delivering business value and creating lasting impact for the communities we serve through technology,” said Pham Minh Tuan, Executive VP of FPT Corporation and CEO of FPT Software. “We aim to bring cutting-edge, AI-First solutions and services to Clearlake’s portfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom